Friday, 6 November 2026European Markets

BIC, PERNOD RICARD, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - bic (bb.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
bic (bb.pa) €66.20 4.4% 12.2%
pernod ricard (ri.pa) €149.95 3.33% 12.18%
ldc (loup.pa) €136.00 1.94% 15.12%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bic (bb.pa)

4.4% forward dividend yield and 12.2% return on equity

société bic sa manufactures and sells stationery, lighter, shaver, and other products worldwide. it offers ball and coloring felt pens, glitter pens, markers, graphic and coloring pencils, shavers, mechanical pencils, sticky notes, printing products, stationery dyes, leads, white boards, correction tapes; pocket, utility, and decorated lighters; paints, gouache, watercolor, gels, highlighters, and various other products. the company also provides refillable shavers, permanent and temporary tattoo markers, semi permanent tattoo, and smart reusable notebooks, kits, crafting accessories, modeling clay and slime, refills, razor for men and women, and razor cartridges. in addition, it sells batteries and shaving preps; and advertising and promotional products. further, the company is involved in the provision of delivery services; production of industrial equipment; manufacture and sale of blades; and manufacture and distribution of it solutions and consumer products, as well as insurance activities. it markets its products primarily under the bic, bic kids, cello, lucky, rocketbook, tipp-ex, bic wite-out, tattly, ami, djeep, inkbox, bic soleil, bic evolution, bodymark, and other brands through a range of channels, including retail mass-market distributors, traditional stores, and office product suppliers, as well as an e-commerce site. the company was founded in 1944 and is headquartered in clichy, france.

earnings per share

as for profitability, bic has a trailing twelve months eps of €4.36.

pe ratio

bic has a trailing twelve months price to earnings ratio of 15.18. meaning, the purchaser of the share is investing €15.18 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.2%.

more news about bic.

2. pernod ricard (ri.pa)

3.33% forward dividend yield and 12.18% return on equity

pernod ricard sa produces and sells wines and spirits worldwide. the company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 pipers, aberlour, absolut, absolut elyx, altos, ararat, augier, avion, ballantine's, becherovka, beefeater, blenders pride, brancott estate, campo viejo, ceder's, chivas, church road, clan campbell, del maguey, george wyndham, green spot, havana club, imperial, imperial blue, italicus, j.p. wiser's, jacob's creek, jameson, jefferson's, kahlúa, kenwood, ki no bi, lillet, long john, l'orbe, lot no. 40, malfy, malibu, martell, method & madness, midleton very rare, minttu, monkey 47, mumm, olmeca, ostoya, passport scotch, pastis 51, pernod, perrier-jouët, plymouth gin, powers, rabbit hole, ramazzotti, redbreast, ricard, royal salute, royal stag, scapa, seagram's gin, secret speyside, smooth ambler, something special, st hugo, stoneleigh, suze, the glenlivet, tx, wyborowa, and ysios. it also provides non-alcoholic beverages under the brands ceder's, suze tonic 0%, cinzano spritz 0%, pacific, campo viejo sparkling 0%, and jacob's creek unvined. pernod ricard sa was founded in 1805 and is headquartered in paris, france.

earnings per share

as for profitability, pernod ricard has a trailing twelve months eps of €8.04.

pe ratio

pernod ricard has a trailing twelve months price to earnings ratio of 18.65. meaning, the purchaser of the share is investing €18.65 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.18%.

sales growth

pernod ricard's sales growth is 7.9% for the present quarter and 7.9% for the next.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on nov 24, 2023, the estimated forward annual dividend rate is 4.7 and the estimated forward annual dividend yield is 3.33%.

yearly top and bottom value

pernod ricard's stock is valued at €149.95 at 12:30 est, way below its 52-week high of €218.00 and higher than its 52-week low of €140.35.

more news about pernod ricard.

3. ldc (loup.pa)

1.94% forward dividend yield and 15.12% return on equity

l.d.c. s.a. produces and sells poultry and processed products in france and internationally. the company also offers ready-cooked dishes, pizzas, pancakes and biscuits, and sandwiches, as well as fresh and frozen products. it offers its products under the le gaulois, maître coq, loué, marie, poule & toque, nature & respect, drosed, goldenfood, and doux brands. the company was founded in 1909 and is based in sablé-sur-sarthe, france.

earnings per share

as for profitability, ldc has a trailing twelve months eps of €16.44.

pe ratio

ldc has a trailing twelve months price to earnings ratio of 8.27. meaning, the purchaser of the share is investing €8.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.12%.

more news about ldc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com